A5111714527- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
- Renal cell carcinoma treatment
- HER2/EGFR in Cancer Research
- Renal and related cancers
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal Tumor Research and Treatment
- Nonmelanoma Skin Cancer Studies
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- Metastasis and carcinoma case studies
- Synthesis of Tetrazole Derivatives
- Advanced Biosensing Techniques and Applications
- Synthesis and biological activity
- Computational Drug Discovery Methods
- Vascular Tumors and Angiosarcomas
- Medical Imaging Techniques and Applications
Radboud University Nijmegen
2014-2025
Radboud University Medical Center
2014-2025
University Medical Center
2021-2025
University Hospital and Clinics
2024-2025
Leiden University Medical Center
2022-2023
Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these will not a durable benefit. Phase 1-2 trials of adoptive cell therapy tumor-infiltrating lymphocytes (TILs) shown promising responses, data from phase 3 are lacking to determine the role TILs treating melanoma.In this 3, multicenter, open-label trial, we randomly assigned unresectable stage IIIC or IV melanoma 1:1 ratio receive TIL...
BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo patients with resected high-risk stage III melanoma. To confirm stability these benefits, longer-term data were needed. METHODS: We randomly assigned 1019 to receive 200 mg or intravenously every weeks for a total 18 doses (approximately 1 year) had 15-, 36-, 42-month median follow-up....
Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting autoimmune disease (AID) have been excluded from clinical trials.To evaluate the safety and efficacy of ICI in advanced melanoma without AID.Nationwide cohort study.The Netherlands.4367 enrolled Dutch Melanoma Treatment Registry (DMTR) between July 2013 2018 followed through February 2019.Patient, clinical, treatment characteristics; irAEs grade...
Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects anti-tumor necrosis factor checkpoint-inhibitor efficacy.To determine the association toxic effect management with progression-free survival (PFS), overall (OS), and melanoma-specific (MSS) in patients advanced melanoma treated first-line ipilimumab-nivolumab combination therapy.This population-based, multicenter cohort study...
Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical in cancer patients. In this phase III trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant nDCs ( n = 99) or placebo 49). Active consisted of intranodally injected autologous CD1c+ conventional plasmacytoid DCs loaded tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas secondary endpoints...
BackgroundThe prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate survival per year diagnosis.MethodsAll systemically treated diagnosed with from 2013 2021 were included Dutch Melanoma Treatment Registry. Baseline characteristics and overall (OS) compared between different years diagnosis. A multivariable Cox proportional hazards model was used estimate association diagnosis OS.FindingsFor this cohort study, we 6260 patients. At baseline,...
Abstract Introduction The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter ongoing debate. In this study, we aim to investigate mass index (BMI) alongside CT-derived metrics the largest cohort date. Methods Patients treated first-line anti-PD1 ± anti-CTLA4 for advanced were retrospectively identified from 11 centers Netherlands. From baseline CT scans, five extracted: subcutaneous adipose tissue index, visceral and skeletal muscle density gauge....
Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate clinical outcomes checkpoint patients with stage III and IV AM compare them cutaneous (CM).We included CM treated first-line anti-programmed cell death (PD)-1 monotherapy or ipilimumab-nivolumab registered prospective nationwide Dutch Melanoma Treatment Registry. Objective response rates, progression-free survival (PFS) overall (OS) were calculated. A...
Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes compared cutaneous (CM) patients treated with anti-PD-1 after complete resection. All stages III-IV AM and CM receiving resection between 2018 2022 were included from prospective nationwide Dutch Melanoma Treatment Registry. We analyzed recurrence-free survival (RFS),...
IMPORTANCE Long-term survival data from clinical trials show that curves of patients with advanced melanoma treated immune checkpoint inhibitors (ICIs) gradually reach a plateau, suggesting have chance achieving long-term survival. OBJECTIVE To investigate in ICIs outside trials. DESIGN, SETTING, AND PARTICIPANTS Cohort study using prospectively collected the nationwide Dutch Melanoma Treatment Registry, including Netherlands first-line 2012 to 2019. Data were analyzed January September...
Abstract Background Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. Methods Data from all advanced melanoma patients treated with BRAFi(/MEKi) were retrieved the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression‐free survival (PFS), and overall (OS) for both first treatment rechallenge. They performed a multivariable logistic regression Cox proportional hazards...
Cutaneous melanoma is a common type of cancer in Adolescents and Young Adults (AYAs, 15–39 years age). However, AYAs are underrepresented clinical trials investigating new therapies the outcomes from these for therefore unclear. Using prospectively collected nation-wide data Dutch Melanoma Treatment Registry (DMTR), we compared baseline characteristics, mutational profiles, treatment strategies, grade 3–4 adverse events (AEs), responses (n = 210) older adults 3775) who were diagnosed with...
: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups.
Abstract The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials support clinical decision‐making. Analysis were performed diagnosed between 2014 and 2017 the Netherlands, immune‐ or targeted therapy, who met ≥1 trial exclusion criteria. These criteria derived from KEYNOTE‐006 CHECKMATE‐067/‐066 trials. Prognostic importance of factors associated overall survival (OS) assessed Kaplan‐Meier method, Cox models, predicted OS...
To evaluate the results of restaging completely resected stage IIIB/C melanoma prior to start adjuvant therapy. One hundred twenty patients with IIIB or IIIC (AJCC 2009) who underwent complete surgical resection were screened for inclusion in our trial investigating dendritic cell therapy (NCT02993315). All imaging exclude local relapse metastasis before entering trial. The frequency recurrent disease within 12 weeks after and method detection investigated. Sixty-nine (58%) 51 (43%)...
Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination both. Aim this study was to assess whether checkpoint related liver metastasis and outcome in a real-world nationwide cohort.Data from prospective Dutch Melanoma Treatment Registry (DMTR) used analyze incidence, risk factors grade 3-4 outcome.2561 advanced cutaneous melanoma patients received...
BackgroundLittle is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, have been registered in DMTR, a population-based registry to monitor quality and safety care Netherlands. This study aims describe treatment patterns, relapse, toxicity rates setting.MethodsAnalyses were performed on included DMTR. Descriptive statistics used analyse patient-, characteristics. A baseline registration completeness analysis was performed, an eligibility...